Determination of silicon in urine by inductive coupled plasma-optical emission spectroscopy

Widner, Bernhard; Mirlach, A.; Hausen, Arno; Jenewein, Ilse; Jenewein, D; Dierich, Manfred P.; Wächter, Helmut; Fuchs, Dietmar

doi:10.1016/s0009-8981(98)00115-6

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of quantitation achieved were 0.04 and 0.09 mmol/L for Al and Fe respectively. Total silicon was determined by inductively coupled plasma emission spectroscopy (ICP-OES) using a modification of a published programme [8].…”

Section: Methodsmentioning

confidence: 99%

Elevated urinary excretion of aluminium and iron in multiple sclerosis

et al. 2006

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central nervous system of as yet unknown aetiology. A consensus of opinion has suggested that the disorder is the result of an interplay between environmental factors and susceptibility genes. We have used a battery of analytical techniques to determine if the urinary excretion of i) markers of oxidative damage; ii) iron and iii) the environmental toxin aluminium and its antagonist, silicon, are altered in relapsing-remitting (RRMS) and secondary progressive MS (SPMS). Urinary concentrations of oxidative biomarkers, MDA and TBARS, were not found to be useful indicators of inflammatory disease in MS. However, urinary concentrations of another potential marker for inflammation and oxidative stress, iron, were significantly increased in SPMS (P<0.01) and insignificantly increased in RRMS (P>0.05). Urinary concentrations of aluminium were also significantly increased in RRMS (P<0.001) and SPMS (P <0.05) such that the levels of aluminium excretion in the former were similar to those observed in individuals undergoing metal chelation therapy. The excretion of silicon was lower in MS and significantly so in SPMS (P<0.05). Increased excretion of iron in urine supported a role for iron dysmetabolism in MS. Levels of urinary aluminium excretion similar to those seen in aluminium intoxication suggested that aluminium may be a hitherto unrecognized environmental factor associated with the aetiology of MS. If aluminium is involved in MS then an increased dietary intake of its natural antagonist, silicon, might be a therapeutic option.

show abstract

Section: Methodsmentioning

confidence: 99%

Elevated urinary excretion of aluminium and iron in multiple sclerosis

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The levels of quantitation achieved were 0.04 and 0.03 µmol/L for Al and Fe respectively. Total Si was determined by inductively coupled plasma emission spectroscopy (ICP-OES) using a modification of a published programme [21]. Reproducibility was consistently within 1% and the validity of calibration was confirmed using the method of standard additions.…”

Section: Measurement Of Al Si Fe and Creatinine In Urinementioning

confidence: 99%

Non-invasive therapy to reduce the body burden of aluminium in Alzheimer's disease

Exley

Korchazhkina

Job

et al. 2006

JAD

View full text Add to dashboard Cite

There are unexplained links between human exposure to aluminium and the incidence, progression and aetiology of Alzheimer's disease. The null hypothesis which underlies any link is that there would be no Alzheimer's disease in the effective absence of a body burden of aluminium. To test this the latter would have to be reduced to and retained at a level that was commensurate with an Alzheimer's disease-free population. In the absence of recent human interference in the biogeochemical cycle of aluminium the reaction of silicic acid with aluminium has acted as a geochemical control of the biological availability of aluminium. This same mechanism might now be applied to both the removal of aluminium from the body and the reduced entry of aluminium into the body while ensuring that essential metals, such as iron, are unaffected. Based upon the premise that urinary aluminium is the best non-invasive estimate of body burden of aluminium patients with Alzheimer's disease were asked to drink 1.5 L of a silicic acid-rich mineral water each day for five days and, by comparison of their urinary excretion of aluminium pre-and post this simple procedure, the influence upon their body burden of aluminium was determined. Drinking the mineral water increased significantly (P < 0.001) their urinary excretion of silicic acid (34.3 ± 15.2 to 55.7 ± 14.2 µmol/mmol creatinine) and concomitantly reduced significantly (P = 0.037) their urinary excretion of aluminium (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). The latter was achieved without any significant (P > 0.05) influence upon the urinary excretion of iron (20.7 ± 9.5 to 21.7 ± 13.8 nmol/mmol creatinine). The reduction in urinary aluminium supported the future longer-term use of silicic acid as non-invasive therapy for reducing the body burden of aluminium in Alzheimer's disease.

show abstract

“…Jackson et al (1998) treated serum samples with highly pure nitric acid (2%) followed by dilution with distilled de-ionized water. Inductively coupled plasma-optical emission spectroscopy (ICP-OES) Widner et al (1998) used ICP-OES to determine silicon in spot urine samples at the three most sensitive emission wavelengths for silicon; that is, 212.412, 251.611 and 288.158 nm. The standard-addition procedure was applied to meet the requirements of matrix compensation in a frequently changing environment.…”

Section: F-aas Dobbie 1982 Et-aasmentioning

confidence: 99%